ESOMEPRAZOLE IN PATIENTS WITH DIARRHEA PREDOMINANT IBS OR FUNCTIONAL DIARRHEA

埃索美拉唑治疗腹泻为主的肠易激综合征或功能性腹泻患者

• 批准号: 7377494
• 负责人: YEHUDA RINGEL
• 金额: $ 1.54万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377494
• 关键词: ESOMEPRAZOLE; PATIENTS; DIARRHEA; PREDOMINANT; IBS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the research study is to determine if Esomeprazole 40 mg qd will improve gastronintestinal (GI) symptoms in patients with diarrhea predominant-IBS or functional diarrhea.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的目的是确定埃索美拉唑40 mg qd是否能改善腹泻型IBS或功能性腹泻患者的胃肠（GI）症状。